original ) (raw )What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
Gökhan Kabaçam
The Turkish Journal of Gastroenterology, 2010
View PDFchevron_right
Review article: Causative factors and clinical management of patients with Crohn’s disease who lose response to anti-TNFφ therapeutics
Kristel Van Steen
2011
View PDFchevron_right
Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study
Vivian Huang
Inflammatory bowel diseases, 2016
View PDFchevron_right
Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy
M. Allez , P. Michetti
Alimentary Pharmacology & Therapeutics, 2011
View PDFchevron_right
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
Philippe Van Hootegem
The Lancet, 2008
View PDFchevron_right
Outcomes of Anti-TNF Treatment in Crohn’s Disease: A Real-Life, Tertiary Center Experience
Simge Saydam
Journal of Enterocolitis, 2022
View PDFchevron_right
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez
Journal of Crohn's and Colitis, 2010
View PDFchevron_right
Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent
Isabel Maria Vera
Digestive and Liver Disease, 2016
View PDFchevron_right
Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study
YAZED ALRUTHIA
Journal of Clinical Medicine, 2022
View PDFchevron_right
Current Practice of Anti-TNF-α Treatment in Inflammatory Bowel Disease: Results From A National Survey in Sweden
Sven Almer
Journal of Gastroenterology and Hepatology Research, 2014
View PDFchevron_right
Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease
Christine Breynaert
Alimentary Pharmacology & Therapeutics, 2019
View PDFchevron_right
Fibrotic Strictures and Anti-TNF-α Therapy in Crohn’s Disease
Giovanni Terrosu
Digestion, 2007
View PDFchevron_right
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâs disease after failure of two other anti-TNF antibodies
Matthieu Allez
Alimentary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study
Sofie Joossens
Gastroenterology, 2003
View PDFchevron_right
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Jean-frédéric Colombel , Brian Feagan
Gastroenterology, 2014
View PDFchevron_right
Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis
Shilan M Mozaffari
Journal of Research in Pharmacy Practice, 2017
View PDFchevron_right
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease
D. Poulain
The American journal of gastroenterology, 2002
View PDFchevron_right
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis
N. Mortensen
Gut, 2006
View PDFchevron_right
Predictive factors for an uncomplicated long-term course of Crohn's disease: A retrospective analysis
josef weismueller
Journal of Crohn's and Colitis, 2013
View PDFchevron_right
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
Gerassimos Mantzaris
Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology
View PDFchevron_right
Autoimmunity associated with anti-tumor necrosis factor ? treatment in Crohn?s disease: a prospective cohort study
Sofie Joossens
Gastroenterology, 2003
View PDFchevron_right
Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease
David Bruining
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2011
View PDFchevron_right
The TNF-α -308 polymorphism may affect the severity of Crohn's disease
Lidiane Bianca Reis
Clinics, 2011
View PDFchevron_right
Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis
Maria de Lourdes Abreu Ferrari
World Journal of Gastroenterology, 2012
View PDFchevron_right
P372 Predicting long-term response to anti-TNFα in Crohn's disease
Peter Bampton
Journal of Crohn's and Colitis, 2012
View PDFchevron_right
Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease
Tsvetelina Velikova
Annals of Colorectal Research, 2018
View PDFchevron_right
Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn’s Disease
Raquel Linares
Inflammatory Bowel Diseases, 2019
View PDFchevron_right
Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations
J.enrique Domínguez-muñoz
European journal of …, 2007
View PDFchevron_right
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
Tom Øresland
Journal of Crohn's and Colitis, 2010
View PDFchevron_right